Evidence map›Paper›PMID 25516915›Full record

ArticleClinical journal of the American Society of Nephrology : CJASN2015

Clinical outcomes after parathyroidectomy in a nationwide cohort of patients on hemodialysis.

Areef Ishani, Jiannong Liu, James B Wetmore, Kimberly A Lowe, Thy Do, Brian D Bradbury, Geoffrey A Block, Allan J Collins

Open access · bronzeAbstract read
In one paragraph

Article in Clinical journal of the American Society of Nephrology : CJASN, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 5 pooled it
8.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 5 syntheses or guidelines pooled it, 137 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Article
  8. Article
  9. Observational
  10. A study of tertiary hyperparathyroidism.Irish journal of medical science · 2025
    Article
  11. Readmission and Cost of Parathyroidectomy By Admission Status in Secondary Hyperparathyroidism.Clinical journal of the American Society of Nephrology : CJASN · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Areef IshaniChronic Disease Research Group, Minneapolis Medical Research Foundation, Minneapolis, Minnesota; Minneapolis Veterans Affairs Health Care System, Minneapolis, Minnesota; Department of Medicine, University of Minnesota, Minneapolis, Minnesota; isha0012@umn.edu.
Jiannong LiuChronic Disease Research Group, Minneapolis Medical Research Foundation, Minneapolis, Minnesota;
James B WetmoreChronic Disease Research Group, Minneapolis Medical Research Foundation, Minneapolis, Minnesota;
Kimberly A LoweCenter for Observational Research, Amgen Inc, Thousand Oaks, California; and.
Thy DoCenter for Observational Research, Amgen Inc, Thousand Oaks, California; and.
Brian D BradburyCenter for Observational Research, Amgen Inc, Thousand Oaks, California; and.
Geoffrey A BlockDenver Nephrology Clinical Research Division, Denver, Colorado.
Allan J CollinsChronic Disease Research Group, Minneapolis Medical Research Foundation, Minneapolis, Minnesota;
Orthopaedic Research Foundation · USAmgen (United States) · USColorado Kidney Care · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesPatients receiving dialysis undergo parathyroidectomy to improve laboratory parameters in resistant hyperparathyroidism with the assumption that clinical outcomes will also improve. However, no randomized clinical trial data demonstrate the benefits of parathyroidectomy. This study aimed to evaluate clinical outcomes up to 1 year after parathyroidectomy in a nationwide sample of patients receiving hemodialysis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Using data from the US Renal Data System, this study identified prevalent hemodialysis patients aged ≥18 years with Medicare as primary payers who underwent parathyroidectomy from 2007 to 2009. Baseline characteristics and comorbid conditions were assessed in the year preceding parathyroidectomy; clinical events were identified in the year preceding and the year after parathyroidectomy. After parathyroidectomy, patients were censored at death, loss of Medicare coverage, kidney transplant, change in dialysis modality, or 365 days. This study estimated cause-specific event rates for both periods and rate ratios comparing event rates in the postparathyroidectomy versus preparathyroidectomy periods.

resultsOf 4435 patients who underwent parathyroidectomy, 2.0% died during the parathyroidectomy hospitalization and the 30 days after discharge. During the 30 days after discharge, 23.8% of patients were rehospitalized; 29.3% of these patients required intensive care. In the year after parathyroidectomy, hospitalizations were higher by 39%, hospital days by 58%, intensive care unit admissions by 69%, and emergency room/observation visits requiring hypocalcemia treatment by 20-fold compared with the preceding year. Cause-specific hospitalizations were higher for acute myocardial infarction (rate ratio, 1.98; 95% confidence interval, 1.60 to 2.46) and dysrhythmia (rate ratio 1.4; 95% confidence interval1.16 to 1.78); fracture rates did not differ (rate ratio 0.82; 95% confidence interval 0.6 to 1.1).

conclusionsParathyroidectomy is associated with significant morbidity in the 30 days after hospital discharge and in the year after the procedure. Awareness of clinical events will assist in developing evidence-based risk/benefit determinations for the indication for parathyroidectomy.

Indexed as

ParathyroidectomyAdultAgedBiomarkersEmergency Service, HospitalFemaleHospital MortalityHumansHyperparathyroidismKidney Failure, ChronicMaleMedicareMiddle AgedParathyroid HormonePatient ReadmissionPostoperative ComplicationsBiomarkersParathyroid HormonePTH protein, humanhemodialysishyperparathyroidismmortality

Identifiers

PMID25516915
PMCPMC4284409
OpenAlexW2143257692

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.